Please assess the completion status of the following clinical trial:

Trial Title: Adherence to Antidepressant Treatment in Subjects With Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Baseline QIDS-SR ≥ 14 (moderate depression)~* Age 18 - 65~* Written Informed Consent~* Major Depressive Disorder, single-episode/recurrent, not in remission~Exclusion Criteria:~* RT2CK17-related exclusions~* Uncontrolled hyperthyroidism~* Glaucoma~* Motor tics~* Monoamine oxidase inhibitor treatment~* Serious coronary artery disease, cardiomyopathy, serious cardiac arrhythmias~* Uncontrolled hypertension~* Peripheral vasculopathy~* Pregnancy~* Bipolar Disorder~* Psychotic Disorder~* History of intolerability of study medications~* Currently taking psychiatric medications~* Current Substance Use Disorder (other than nicotine)~* Current Alcohol Use Disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Escitalopram + RT2CK17 (Type: ACTIVE_COMPARATOR): 10mg escitalopram + 5mg RT2CK17 will be given orally and encapsulated into one capsule, once per day for 8 weeks. The capsules will be produced in the same manner as the placebo comparator by a local compounding pharmacy in Tulsa, Oklahoma.
- Escitalopram + Placebo (Type: PLACEBO_COMPARATOR): 10mg escitalopram + 5mg placebo will be given orally and encapsulated into one capsule, once per day for 8 weeks. The capsules will be produced in the same manner as the active comparator by a local compounding pharmacy in Tulsa, Oklahoma.

Based on this trial design, predict the completion outcome and termination type (if applicable).